Results 41 to 50 of about 49,586 (211)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

Cardiac Failure Review, 2020
Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis.
Sebastiaan HC Klaassen, Dirk J van Veldhuisen, Hans LA Nienhuis, Maarten P van den Berg, Bouke PC Hazenberg, Peter van der Meer   +5 more
doaj   +1 more source

Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review

BMC Musculoskeletal Disorders, 2023
Background Hereditary and wild-type transthyretin-mediated (ATTRv and ATTRwt) amyloidoses result from the misfolding of transthyretin and aggregation of amyloid plaques in multiple organ systems.
Emre Aldinc, Courtney Campbell, Finn Gustafsson, Abigail Beveridge, Richard Macey, Laura Marr, Catherine Summers, Dafang Zhang   +7 more
doaj   +1 more source

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis

Nature Communications, 2022
This manuscript reports the structure of a pathologically relevant wild type ATTR amyloid fibril from systemic non-hereditary transthyretin amyloidosis.
Maximilian Steinebrei, Juliane Gottwald, Julian Baur, Christoph Röcken, Ute Hegenbart, Stefan Schönland, Matthias Schmidt   +6 more
doaj   +1 more source

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis

ESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.
Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò, Mattia Zampieri, Carlotta Mazzoni, Carlo Fumagalli, Michela Baccini, Alessandra Mattei, Alberto Cipriani, Laura De Michieli, Aldostefano Porcari, Gianfranco Sinagra, Marco Merlo, Giacomo Tini, Beatrice Musumeci, Domitilla Russo, Pier Filippo Vianello, Marco Canepa, Roberto Licordari, Gianluca di Bella, Claudio Rapezzi, Federico Perfetto, Francesco Cappelli   +20 more
wiley   +1 more source

Subclinical Cardiac Involvement in Asymptomatic ATTR Mutation Carriers: Insights from Cardiac MRI, Myocardial Strain, and Mapping Techniques

Journal of Cardiovascular Development and Disease
Transthyretin cardiac amyloidosis (ATTR-CA) leads to myocardial infiltration, affecting prognosis and survival. Diagnosing early-stage ATTR-CA remains challenging due to its subtle manifestations.
Luca Conia, Daria Filatova, Giacomo Pambianchi, Livia Marchitelli, Giulia Cundari, Giuseppe Stancanelli, Maria Alfarano, Giulia Marchionni, Cristina Chimenti, Carlo Catalano, Nicola Galea   +10 more
doaj   +1 more source

Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement

Journal of Cardiovascular Development and Disease, 2022
There have been several reports on the identification of the stage of transthyretin amyloid cardiomyopathy (ATTR-CM); however, a staging system for ATTR-CM has not yet been established.
Yoshitaka Isotani, Eisuke Amiya, Junichi Ishida, Issei Komuro   +3 more
doaj   +1 more source

ATTR Gene Variants in HCM

JACC: Case Reports
Hypertrophic cardiomyopathy is the most common inherited cardiomyopathy, with a prevalence of 1:200 to 1:500. Cardiac amyloidosis, another cardiomyopathy caused by myocardial deposition of abnormally folded TTR protein, can be acquired or hereditary. The presence of pathogenic TTR gene variants in patients with phenotypic HCM is an underrecognized and ...
Anthony J. Kanelidis, Jeremy A. Slivnick, Rachel Campagna, Bryan Smith, Sara Kalantari, Nitasha Sarswat, Gene Kim   +6 more
openaire   +4 more sources

Imaging cardiac ATTR amyloid [PDF]

Orphanet Journal of Rare Diseases, 2015
The heart is the principal site of involvement in non-hereditary ATTR amyloidosis and a major driver of treatment options and prognosis in hereditary forms of the disease. The goals of cardiac imaging in amyloidosis are to aid diagnosis, provide prognostic information, track disease progression and evaluate response to therapy.
openaire   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Transthyretin cardiac amyloidosis in patients after TAVR: clinical and echocardiographic findings and long term survival

ESC Heart Failure, 2021
Aims The aim of this study was to examine the prevalence of amyloid transthyretin (ATTR) cardiac amyloidosis in patients 1–2 years after trans‐catheter aortic valve replacement (TAVR) and to assess their clinical and echocardiographic outcome and long ...
Sara Shimoni, Meital Zikri, Dan Haberman, Shay Livschitz, Sagi Tshori, Yacov Fabricant, Valery Meledin, Gera Gandelman, Sorel Goland, Jacob George   +9 more
doaj   +1 more source